Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.61 |
| ▸ | RAB9A | P51151 | 5/20 | 0.61 |
| ▸ | NPC1 | O15118 | 4/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.61 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.61 |
| ▸ | RELA | Q04206 | 2/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16161600 | 0.97 | RAB9A (0.58) | SMN1; SMN2RAB9ANPC1NFKB1NFKB2 | |
| Dimethylamine SCHEMBL2599649 | 0.91 | SMN1; SMN2 (0.52) | SMN1; SMN2RAB9ANPC1NFKB1NFKB2 | |
| SCHEMBL16225037 | 0.83 | CYP2A6 (0.50) | SMN1; SMN2RAB9ANPC1NFKB1NFKB2 | |
| SCHEMBL8098714 | 0.83 | NPC1 (0.35) | SMN1; SMN2RAB9ANPC1NFKB1NFKB2 | |
| SCHEMBL1743253 | 0.79 | NPC1 (0.52) | SMN1; SMN2RAB9ANPC1CYP1A2MEN1 | |
| SCHEMBL21852916 | 0.77 | MAPT (0.55) | SMN1; SMN2KDM4ELMNAMAPTNOTUM | |
| Biphenyl SCHEMBL27769446 | 0.77 | ATM (0.48) | SMN1; SMN2RAB9ANPC1NFKB1NFKB2 | |
| SCHEMBL10898685 | 0.77 | MAP4K4 (0.50) | SMN1; SMN2RAB9ANPC1KMT2AMAP4K4 | |
| SCHEMBL444885 | 0.77 | CYP2A6 (0.68) | SMN1; SMN2CYP1A2ALDH1A1MEN1HPGD | |
| SCHEMBL2117282 | 0.76 | NPC1 (1.00) | SMN1; SMN2RAB9ANPC1NFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110327467-A | The composition that is made of the auxiliary material of hydroxyl and pyrimidines and containing the pharmaceutical preparation of the composition | 黄泳华 | 2019-10-15 | — | — | CN | claimed |
| US-12356856-B2 | Plurality of host materials and organic electroluminescent device comprising the same | DUPONT SPECIALTY MATERIALS KOREA LTD. (KR) | 2025-07-08 | — | — | US | disclosed |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| WO-2025067457-A1 | HETEROCYCLIC FUSED RING COMPOUND, AND COMPOSITION AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2025-04-03 | — | — | WO | disclosed |
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | ENANTA PHARM INC (US) | 2024-10-31 | — | — | US | disclosed |
| US-20240327412-A1 | FACTOR XIIA INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2024-10-03 | — | — | US | disclosed |
| US-11952389-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| EP-3687543-B1 | COMBINATIONS OF PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| WO-2004022556-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONIST | NOVARTIS AG (CH) | 2004-03-18 | — | — | WO | disclosed |
| CN-1468232-A | Heterocyclic sodium/proton exchange inhibitors and method | ����˹�ж�-����˹˹������˾ | 2004-01-14 | — | — | CN | disclosed |
| EP-1212299-A1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca UK Limited (GB) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001014333-A1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LIMITED (GB) | 2001-03-01 | — | — | WO | disclosed |
| EP-0519370-B1 | Heterocyclic derivatives | MERCK PATENT GMBH (DE) | 1997-11-05 | — | — | EP | disclosed |
| EP-0532178-B1 | Methanoanthracenes as dopamine antagonists | ZENECA LTD (GB) | 1996-10-16 | — | — | EP | disclosed |
| US-5455246-A | Treating neuropsychiatric disorders | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1995-10-03 | — | — | US | disclosed |
| US-5266570-A | Neuropsychiatric disorders | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-11-30 | — | — | US | disclosed |
| EP-0532178-A1 | Methanoanthracenes as dopamine antagonists | ZENECA LIMITED (GB) | 1993-03-17 | — | — | EP | disclosed |
| US-4209621-A | TRANQUILIZERS | AMERICAN CYANAMID COMPANY (US) | 1980-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | GABRA5, GABRA1, GABBR2 | SMN1; SMN2 627/4885RAB9A 1384/4885NPC1 224/4885 |
| US-12356856-B2 | Plurality of host materials and organic electroluminescent device comprising the same | TELO2, LIMS1, TERT | SMN1; SMN2 113/4885RAB9A 2487/4885NPC1 3518/4885 |
| US-11952389-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | SMN1; SMN2 627/4885RAB9A 1384/4885NPC1 224/4885 |
| US-20240327412-A1 | FACTOR XIIA INHIBITORS | F11, F13B, F12 | SMN1; SMN2 3191/4885RAB9A 2183/4885NPC1 3064/4885 |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | SMN1; SMN2 627/4885RAB9A 1384/4885NPC1 224/4885 |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ACE, ACE2, SPCS3 | SMN1; SMN2 591/4885RAB9A 384/4885NPC1 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.